These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8718425)

  • 1. Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
    Koch P; Johnson N; van Schaik J; Andersen S; Blatter J; Bosanquet N; Copley-Merriman K; Drings P
    Anticancer Drugs; 1995 Dec; 6 Suppl 6():49-54. PubMed ID: 8718425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
    Copley-Merriman C; Corral J; King K; Whiteside R; Voi M; Dorr FA; McDonald RC
    Lung Cancer; 1996 Feb; 14(1):45-61. PubMed ID: 8696720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
    Tennvall GR; Fernberg JO
    Med Oncol; 1998 Jul; 15(2):129-36. PubMed ID: 9789222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic value of gemcitabine in non-small cell lung cancer.
    Copley-Merriman C; Martin C; Johnson N; Sacristan JA; Drings PA; Bosanquet N
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):90-8. PubMed ID: 8893889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
    Evans WK
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-56-S7-63. PubMed ID: 9194482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
    Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
    Minshall ME; Liepa AM
    Am J Manag Care; 1998 Nov; 4(11):1591-602. PubMed ID: 10338905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
    Sacristán JA; Kennedy-Martin T; Rosell R; Cardenal F; Antón A; Lomas M; Alberola V; Massuti B; Carrato A; Minshall M
    Lung Cancer; 2000 May; 28(2):97-107. PubMed ID: 10717327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
    Szczepura A
    Lung Cancer; 2002 Nov; 38 Suppl 2():S21-8. PubMed ID: 12431825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
    Palmer AJ; Brandt A
    Monaldi Arch Chest Dis; 1996 Aug; 51(4):279-88. PubMed ID: 8909011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic evaluation of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patient in an outpatient setting].
    Min SH; Ko SK; Lim JY
    Taehan Kanho Hakhoe Chi; 2008 Jun; 38(3):363-71. PubMed ID: 18604145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
    Maniadakis N; Fragoulakis V; Pallis A; Prezerakos P; Georgoulias V
    Lung Cancer; 2007 Nov; 58(2):275-81. PubMed ID: 17688969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen P; Liippo K; Mattson K; van Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; van Walree N; ten Bokkel-Huinink W
    Ann Oncol; 1997 Jun; 8(6):525-9. PubMed ID: 9261520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.
    Cucević B; Samarzija M; Baricević D; Jakopović M; Redzepi G; Samija M
    Coll Antropol; 2005 Dec; 29(2):583-8. PubMed ID: 16417165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
    Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
    ten Bokkel Huinink WW; Bergman B; Chemaissani A; Dornoff W; Drings P; Kellokumpu-Lehtinen PL; Liippo K; Mattson K; von Pawel J; Ricci S; Sederholm C; Stahel RA; Wagenius G; Walree NV; Manegold C
    Lung Cancer; 1999 Nov; 26(2):85-94. PubMed ID: 10568679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
    Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
    Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.